NCT07102706

Phase I Trial of GR1803 Injection in Patients With RRMM

A Phase I Monotherapy Study Assessing the Safety and Efficacy of GR1803, a BCMA×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 76 (actual)
• Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

All subjects will receive GR1803 injection until intolerable toxicity or investigator-assessed disease progression occurs (except in cases of disease progression due to discontinuation of the drug as a result of an adverse event) or until the subject has been administered the drug for 52 weeks or until the subject withdraws consent or until the investigator determines that the subject needs to be discontinued.

Conditions

• Multiple Myeloma (MM)

Interventions

Type	Name	Description
DRUG	GR1803 injection	weekly dose up to week 24 , biweekly dose from week 24 to week 36, and triweekly dose from week 36 to week 52

Timeline

• Start date: 2022-05-27
• Primary completion: 2025-05-20
• Completion: 2025-05-20
• First posted: 2025-08-05
• Last updated: 2025-08-05

Locations

1 site across 1 country: China